Added to YB: 2025-11-20
Pitch date: 2025-11-18
DCTH [bullish]
Delcath Systems, Inc.
-5.86%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Market Cap
$304.1M
Pitch Price
$8.70
Price Target
14.36 (+69%)
Dividend
N/A
EV/EBITDA
34.97
P/E
249.52
EV/Sales
2.71
Sector
Health Care Equipment and Supplies
Category
growth
This Could Be the Next Multi-Indication Oncology Multibagger - Delcath Systems, Inc.
DCTH: FDA-approved Hepzato Kit for liver-dominant cancers, revenue +150% YoY to $83-85M guidance, 87% gross margin, positive EBITDA. Phase 2 trials in colorectal/breast cancer 2025-26. 36% ORR in mUM vs historical benchmarks. $89M cash, no debt. Risk-weighted target $14.36 (+67% upside).
Read full article (6 min)